NASDAQ: DMACDiamedica Therapeutics Inc Stock
$1.56-0.03 (-1.89%)
Updated Mar 27, 2023
DMAC Price
$1.56
Fair Value Price
$1.85
Market Cap
$41.12M
52 Week Low
$1.12
52 Week High
$2.71
P/E
-3.24x
P/B
1.17x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$12M
Beta
0.71
Next Earnings
May 3, 2023
Ex-Dividend
N/A
Next Dividend
N/A
DMAC Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DMAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMAC ($1.56) is undervalued by 15.95% relative to our estimate of its Fair Value price of $1.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DMAC ($1.56) is not significantly undervalued (15.95%) relative to our estimate of its Fair Value price of $1.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DMAC due diligence checks available for Premium users.
Be the first to know about important DMAC news, forecast changes, insider trades & much more!
DMAC News
Valuation
DMAC fair value
Fair Value of DMAC stock based on Discounted Cash Flow (DCF)
Price
$1.56
Fair Value
$1.85
Undervalued by
15.68%
DMAC ($1.56) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DMAC ($1.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DMAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.24x
Industry
18.55x
Market
21.44x
DMAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
4.86x
DMAC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DMAC's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
DMAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$37.0M
Liabilities
$2.0M
Debt to equity
0.06
DMAC's short-term assets ($36.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMAC's short-term assets ($36.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$2.1M
Financing
-$2.0k
DMAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMAC vs Biotech Stocks
Diamedica Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.